The Role of Levosimendan as Inotropic Agent in Acute Aluminum Phosphide-induced Cardiotoxicity

Inclusion Criteria: Patients with acute ALP intoxication admitted to ICU of PCC-ASUH and developed cardiotoxicity with Poisoning Severity Score (PSS) 2 (moderate) or 3 (severe) that led to cardiogenic shock and necessitated administration of vasoactive medications Exclusion Criteria: * Pregnant patients * The presence of pre-existing diseases such as hematologic, pulmonary, hepatic, renal, immunologic, central nervous system, or endocrine system disorders that made patients unsuitable for the present study. * Patients with underlying cardiac disease and ECG changes, especially prolonged QTc intervals. * Patients co-ingested drugs or toxins with cardiovascular toxicity. * Patients had been previously administered with inotropic agent other than agents under the current study as a preconsultation treatment. * Patients had received any other investigational medicinal products within 30 days or were enrolled in any other interventional trials with the potential to interact with Levosimendan or affect ALP induced cardiotoxicity